Recoil Therapeutics
Investor Deck

Longevity Biomaterials Platform

Rebuilding tissue mechanics in aging-related structural decline.

We engineer injectable biomaterials designed to restore extracellular matrix architecture and elasticity, beginning with skin as an accessible first proof point.

Contact TeamExplore Science

Why now

$4.4T
U.S. annual spend on aging-linked chronic disease
90%
Healthcare expenditure tied to age-associated conditions
1
A structural-repair thesis for aging tissues.

Science

A structural-repair thesis for aging tissues.

Many aging tissues lose mechanical function as their extracellular matrix breaks down. Our strategy restores lost extracellular fiber mechanics to rebuild the physical microenvironment required for durable tissue function.

Why It Matters

Loss of collagen and elastic fibers degrades structure, triggers dysfunction, and accelerates aging-driven disease across tissues.

  • Aging burden dominates national healthcare costs
  • Current therapies manage symptoms, not mechanics
  • Structural restoration can create durable effect

What We Build

Synthetic biomaterials designed to reconstitute ECM-like fibers and enable native-like mechanical behavior.

  • Synthetic biomaterials for ECM-inspired structural repair
  • Localized delivery with strong safety rationale
  • Platform architecture for multiple indications

Why We Start Here

A clear first indication with a de-risked translational path and expansion into broader degenerative tissue markets.

  • Lead indication: skin
  • Fast iteration through ex vivo readouts
  • Scalable to cartilage and disc degeneration

Platform

Initial indication and expansion map

We are evaluating skin as an accessible first proof point, then expand into mechanically-driven degeneration areas with shared biological logic.

Skin

Skin

Lead program · collagen + elastin breakdown

🦴

Joint Cartilage

cartilage matrix loss

Intervertebral Disc

Intervertebral Disc

collagen/proteoglycan matrix failure

Injectable biomaterial approach overview

Financing

Structured path from proof to clinical readiness

Recoil is raising a pre-seed technical proof round. Details available upon request.

Discuss the Round

Team

Scientist-founder team with translational depth

Faizan Zubair

Co-Founder & CEO

Chemical & Biomolecular Engineering PhD 10 years in pharma and startups

Joseph Kuo

Co-Founder & COO

Immunology PhD · MBA Business development in life sciences

Christian Croxton

Biomaterials Lead

Biomaterials and implantable medical devices

Paul Laibinis

Scientific Advisor

Chair of Chemical Engineering at Vanderbilt Self-assembly and organic chemistry

Aubrey de Grey

Scientific Advisor

President & CSO at LEV Foundation ECM biology and longevity

Kelly Smith

Regulatory Advisor

CMC, Regulatory, and CMC